| Autor: |
Kapui Z; Chinoin Pharmaceutical and Chemical Works Co., Ltd., Budapest, Hungary., Mikus EG, Bence J, Gerber K, Boér K, Korbonits D, Borsodi A, Arányi P |
| Jazyk: |
angličtina |
| Zdroj: |
Arzneimittel-Forschung [Arzneimittelforschung] 1998 Dec; Vol. 48 (12), pp. 1147-55. |
| Abstrakt: |
CH-13584 (formerly: KHL-8425, 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl], CAS 115779-20-9) showed antitussive effect on the citric acid spray-induced cough model. The antitussive effect of p.o. CH-13584 was antagonised by i.m. or intracerebroventricular (i.c.v.) naloxone, i.m. nor-binaltorphimine or s.c. beta-funaltrexamine. Intracerebroventricular administration of CH-13584 induced long-lasting antitussive effect which was antagonised by coadministration of i.c.v. naloxone. CH-13584 did not bind to opioid mu, delta, kappa receptor in vitro or inhibit the [3H]diprenorphine binding in vivo. Two-week treatment with CH-13584 up to the dose of 100 mg/kg p.o. did not produce autonomic and behavioural signs of withdrawal induced either by drug withdrawal or by naloxone injection, while morphine and codeine induced characteristic opioid-type physical dependence in rats. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
